SRX3305
SRX3305 is an BTK/PI3K/BRD4 inhibitor with IC50s of 6.5 nM, 15 nM, and 4 nM toward BTK, PI3Kɑ and PI3Kδ, respectively. SRX3305 attenuates chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 yields potent anti-tumor effects but spares healthy bystander cells. SRX3305 inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals. SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13. SRX3305 maintains its anti-tumor effects in Ibrutinib (HY-10997)-resistant CLL cells. SRX3305 can be used for research in CLL, diffuse large B-cell lymphoma (DLBCL) and MCL.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2409965-28-0
- Formule: C22H20N2O5S
- Masse moléculaire:424.47
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[2]|
PI3Kα 15 nM (IC50) |
PI3Kδ 4 nM (IC50) |
In Vitro
SRX3305 (0.1-100 μM; 72 h) inhibits proliferation with an average IC50 of 1.38 µM across B-cell non-Hodgkin lymphoma (B-NHL) cell lines[1].
SRX3305 (0.1-100 μM; 72 h) reduces cell proliferation in DLBCL cells with IC50 values of ~290 nM in OCI-LY3 cells and ~920 nM in SU-DHL-6 cells[1].
SRX3305 (0.5-2 μM; 24-48 h) induces apoptosis in HG-3 and OSU-CLL cells in a dose-dependent manner[1].
SRX3305 (0.5-2 μM; 4 h) inhibits critical BCR survival signaling in OSU-CLL, MEC-1 and MEC-2 cell lines[1].
SRX3305 (0.16-5 μM; 48 h) inhibits primary malignant B-cell survival and proliferation in malignant B-cells isolated from Eμ-TCL1 (CLL model) and Eμ-Myc/TCL1 mice[1].
SRX3305 (0.5-2 μM; 48 h) disrupts stroma survival support and chemokine-induced migration in CLL[1].
SRX3305 (0.5-2 μM; 48 h) can overcome TME-induced survival signaling in MEC-1 cells[1].
SRX3305 (0.1-100 μM; 72 h) is active in ibrutinib-resistant HG-3 cells[1].
SRX3305 (10 nM-100 μM; 48 h) shows an IC50 of 1 nM in Mino cells, 58 nM in JeKo-1 cells, 1.1 μM in Granta cells, 1 μM in JeKo-1 BTK C481S mutant cells and 47 nM in Mino BTK C481S mutant cells[2].
SRX3305 (0.375-2 μM; 48 h) is minimally toxic to healthy donor peripheral blood mononuclear cells (PBMCs) or bystander healthy stromal cells and has low toxicity to healthy donor B-cells[2].
SRX3305 (0.1-10 μM; 48 h) has anti-tumor effect in primary Eμ-Myc tumor samples[2].
SRX3305 (0.01-0.5 μM; 1 h) blocks activation of both BTK and AKT[2].
SRX3305 (0.01-1 μM; 1 h) shows improved efficacy in MCL and Ibrutinib-resistant MCL cells[2].
SRX3305 (1 h) retains inhibition of BTK and AKT phosphorylation in Mino cells after inhibitor wash out experiments[2].
SRX3305 (0.5-2 μM; 24 h) inhibits JeKo-1 and Mino cells proliferation through inducing S/G2 phase cell cycle arrest and promoting apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B-cell non-Hodgkin lymphoma cell lines
-
Concentration:0.1 μM; 1 μM; 10 μM; 100 μM
-
Incubation Time:72 h
-
Result:Significantly inhibited CLL cell proliferation in a dose-dependent manner.
-
Cell Line:HG-3 and OSU-CLL cell lines
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:24 h; 48 h
-
Result:Induced apoptosis in a dose-dependent manner.
-
Cell Line:OSU-CLL, MEC-1 and MEC-2 cell lines
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:4 h
-
Result:Effectively inhibited the phosphorylation of BTK and PRAS40 (indicative of PI3K/AKT signaling) and reduced MYC expression.
-
Cell Line:OSU-CLL and MEC-1 cell lines
-
Concentration:0.5 μM plus inhibitor treatment; 1 μM plus inhibitor treatment; 2 μM plus inhibitor treatment
-
Incubation Time:4 h
-
Result:Decreased phosphorylation of BTK (p-BTK) and PRAS40 (p-PRAS40) and reduced MYC expression in continuous inhibitor treatment.
Retained the inhibition of p-BTK following treatment washout.
Marked inhibition of p-PRAS40 and MYC expression after treatment washout was maintained.
-
Cell Line:patient-derived CLL cells
-
Concentration:0.16 μM plus CpG (3.2 μM); 0.31 μM plus CpG (3.2 μM); 0.63 μM plus CpG (3.2 μM); 1.25 μM plus CpG (3.2 μM); 2.5 μM plus CpG (3.2 μM); 5 μM plus CpG (3.2 μM)
-
Incubation Time:48 h
-
Result:Reversed CpG ODN-mediated proliferation reflected by reduced MYC levels in primary CLL cells.
-
Cell Line:patient-derived CLL cells
-
Concentration:0.5 μM plus CpG (3.2 μM); 1 μM plus CpG (3.2 μM); 2 μM plus CpG (3.2 μM)
-
Incubation Time:48 h
-
Result:Induced the accumulation of P21 (cyclin-dependent kinase inhibitor), indicative of cell cycle arrest.
Did not influence the proliferation under unstimulated/basal conditions.
-
Cell Line:malignant B-cells isolated from Eμ-TCL1 (CLL model) and Eμ-Myc/TCL1 mice
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:48 h
-
Result:Induced significant cytotoxicity in Eμ-TCL1 and Eμ-Myc/TCL1-derived malignant cells in a dose-dependent manner, suggesting promising therapeutic benefits in aggressive CLL and associated lymphomas.
-
Cell Line:co-culture of primary CLL cells on BM-derived stromal cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:48 h
-
Result:Reduced CLL cell viability in a dose-dependent manner despite stroma protection.
Did not have toxicity to the stromal cells, indicating that CLL cell cytotoxicity is not a function of reduced stroma viability.
-
Cell Line:MEC-1 cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:48 h
-
Result:Reduced the migration of MEC-1 cells towards CXCL-12 or CXCL-13.
-
Cell Line:ibrutinib-resistant HG-3 cells
-
Concentration:0.1 μM; 1 μM; 10 μM; 100 μM
-
Incubation Time:72 h
-
Result:Remarkably decreased cell proliferation.
-
Cell Line:ibrutinib-resistant HG-3 cells
-
Concentration:1 μM; 2 μM
-
Incubation Time:4 h
-
Result:Consistently decreased MYC expression and p-PRAS40 (PI3K target) and increased P21 levels in IR-HG3 cells.
Reduced BTK activation (phosphorylation).
-
Cell Line:MCL cell lines JeKo-1, Mino, JeKo-1 BTK C481S and Mino BTK C481S
-
Concentration:10 nM; 100 nM; 1 μM; 10 μM; 100 μM
-
Incubation Time:48 h
-
Result:Exhibited strong anti-proliferative function.
-
Cell Line:PBMCs
-
Concentration:0.375 μM; 0.75 μM; 1.5 μM
-
Incubation Time:48 h
-
Result:Had minimally toxicity.
-
Cell Line:healthy donor B-cells
-
Concentration:0.5 μM
-
Incubation Time:48 h
-
Result:Exhibited low toxicity.
-
Cell Line:bystander healthy stromal cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:48 h
-
Result:Had minimally toxicity.
-
Cell Line:primary Eμ-Myc tumor cells
-
Concentration:0.1 μM; 0.3 μM; 1 μM; 3.2 μM; 10 μM
-
Incubation Time:48 h
-
Result:Exhibited anti-tumor effect.
-
Cell Line:IgM stimulated JeKo-1 and Mino cells
-
Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM
-
Incubation Time:1 h
-
Result:Decreased BTK phosphorylation at Tyr223 and AKT phosphorylation at Ser473.
-
Cell Line:IgM-stimulated Granta cells
-
Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM; 1 μM
-
Incubation Time:1 h
-
Result:Showed dose dependent anti-proliferative activity.
-
Cell Line:JeKo-1 cells
-
Concentration:0.5 μM
-
Incubation Time:24 h
-
Result:Decreased the expression of cMYC.
Increased the expression of HEXIM1.
-
Cell Line:JeKo-1 and Mino cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in JeKo-1 and Mino cells in a concentration-dependent manner.
-
Cell Line:JeKo-1 and Mino cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Increased cell population in S phase and G2 phase.
Chemical Information
-
CAS No. 2409965-28-0
-
Masse moléculaire 424.47
-
Formule C22H20N2O5S
-
SMILES
O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC5=C(OCCN5C(C=C)=O)C=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
Pureté et documentation
Références
[1]. Smith AL, et al. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2022 Jun 16;23(12):6712. [Content Brief]
[2]. Vann KR, et al. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. Mol Biomed. 2022 Jan 15;3(1):2. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)